Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

THE ROLE OF THYMIDYLATE SYNTHETASE IN THE EFFICACY OF TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA WITH PEMETREXED/CISPLATIN REGIMENS VERSUS GEMCITABINE/CISPLATIN

DOI: https://doi.org/10.29296/25877313-2018-03-08
Download full text PDF
Issue: 
3
Year: 
2018

T.D. Karpenko Thephysician of the Surgical Department №13 Thoraco-Abdominal Department, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow); Senior Laboratory Assistant, Department of Oncology, Faculty of Post-Graduate Further Education, MSMSU after. A.I. Evdokimov (Moscow) E-mail: katan4ik@list.ru N.A. Kozlov Ph.D. (Med.), Head of Pathology Department, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) E-mail: newbox13@mail.ru L.E. Rotobelskaya Research Scientist, Department of Radiology and Diagnosis, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) E-mail: lidar@mail.ru S.G. Bagrova Research Scientist, Department of Chemotherapy, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) B.E. Polotskiy Dr.Sc. (Med.), Professor, Senior Research Scientist, Thoracic Department of Thoraco-Abdominal Oncology Department, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) E-mail: polotskiy.boris@yandex.ru K.K. Laktionov Dr.Sc. (Med.), Head of the Department №13 Thoraco-Abdominal Department, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) E-mail: lkoskos@mail.ru M.B. Bychkov Dr.Sc. (Med.), Professor, Senior Research Scientist, Department of Chemotherapy, Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) E-mail: mbychkov77@yandex.ru

Standard 1-line treatment for disseminated MPM is systemic chemotherapy based on Platinum drugs in combination with pemetrexed or raltitrexed. This combination showed an increase of objective responses, time to progression, overall survival and quality of life compared with cisplatin alone. Another scheme of combination chemotherapy that was used with effective enough until the advent of pemetrexed in clinical practice is a combination of gemcitabine plus Platinum drugs. The objective effect can be obtained in 45% of patients dute to combined chemotherapy. We investigated whether thymidylate synthase (TS) expression is a predictive marker for the clinical outcome of pemetrexed/cisplatin in patients with malignant pleural mesothelioma. From January 2006 to November 2016 in the department of chemotherapy Federal State Budgetary Institution «SMRC Oncology. N.N. Blokhin» of the Russian Ministry of Health (Moscow) selected 53 patients who underwent the first line of treatment with pemetrexed or gemcitabine in combination with platinum. The average age was 52.5 years (from 29 to 76 years). There were 28 men (52.8%), women - 25 (47.2%). With stage II 3.4% (1), stage III - 30% (9) and with stage IV - 66.6% (20). Epithelioid MPM was detected - 73.3%. ECOG 0 - 36.7% (11), ECOG 1 53.3% (16) and ECOG 2 - 10% (3). All patients were divided into two groups depending on the expression of TS in tumor cells: TSnegative group 53.3% (16) and TS-positive group 46.6% (14). Additionally, patients were divided into two groups, depending on the chemotherapy regimen used. The rate of objective responses (ROO) in the TS-negative group was 55% in the pemetrexed / cisplatin group and 57% in the gemcitabine / cisplatin group. For TS-positive group accounted for 22% and 40%, respectively. The data allow us to consider the expression of TS as a potential prognostic marker. Additional prospective studies involving larger cohorts may confirm the predictive role of TS expression in tumor cells in the treatment of MPM.
Keywords: 
pleural mesothelioma
predictors of the effectiveness of chemotherapy
thymidylate synthetase

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Danenberg P.V. Thymidylate synthase: a target enzyme in cancer chemotherapy // Biochim. Biophys. Acta. 1977. № 473. R. 73–92.
  2. Absaljamova O.V., Stepanova E.V., Lichinitser M.R. Znachenie urovnja timidilatsintetazy dlja prognoza i effekta himioterapii pri kolorektal'nom rake // Sovremennaja onkologija. 2004. № 4. S. 155−157.
  3. Adjei A. Pharmacology and mechanism of action of pemetrexed // Clin Lung Cancer. 2004. V. 5. № 2. P. 51−55.
  4. Calvert A. Biochemical Pharmacology of pemetrexed // Oncology. 2004. V. 18. № 13. R. 13−17.
  5. Hanauske A., Chen V., et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors // The Oncol. 2001. № 6. R. 363−373.
  6. Hashimoto H., Ozeki Y., Sato M., et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung // Cancer. 2006. № 106. R. 1595– 1601.
  7. Ozasa H., Oguri T., Uemura T., et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer // Cancer Sci. 2010. № 101. R. 161–166.
  8. Chen C., Chang Y., Shih J., et al. Thymidylate synthase and dihydrofolate reductase expression in non–small-cell lung carcinoma: The association with treatment efficacy of pemetrexed // Lung Cancer. 2011. № 74. R. 132–138.
  9. Christoph D.C., Asuncion B.R., Hassan B., et al. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non–small-cell lung cancer treated with pemetrexed // J. Thorac. Oncol. 2013. № 8. R. 19–30.
  10. Nicolson M.C., Fennell D.A., Ferry D., et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non–small-cell lung cancer in a prospective blinded assessment phase II clinical trial // J. Thorac. Oncol. 2013. № 8. R. 930–939.
  11. Travis W.D., Brambilla E., Burke A.P., Marx A., and Nicholson A.G. WHO Classification of Tumours of the Lung, Pleura. Thymus and Heart.International Agency for Research on Cancer. Lyon, France. 2015.
  12. Jong-Mu Sun, et al. Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial // J. of Clin. Oncol. 2015. V. 22. № 33. R. 2450−2456.
  13. Myrne M.J., Nowak A.K. Modified RECIST criteria of assessment of response in malignant pleural mesothelioma // Ann. Oncol. 2004. № 15. R. 257−260.
  14. Bychkov M.B., Bagrova S.G., Karpenko T.D. Stabilizatsija bolezni kak vazhnyj faktor otsenki effektivnosti lechenija i prognoza vyzhivaemosti u onkologicheskih bol'nyh // Rossijskij onkologicheskij zhurnal. 2016. T. 21. № 1−2. S. 6−10.
  15. Sun J.M., Han J., Ahn J.S., et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non–small-cell lung cancer treated with pemetrexed-based chemotherapy // J. Thorac Oncol. 2011. № 6. R. 1392–1399.
  16. Bychkov M.B., Bagrova S.G., Karpenko T.D., Kuz'minov A.E. Prakticheskie rekomendatsii po lekarstvennomu lecheniju mezoteliomy plevry // Zlokachestvennye opuholi. 2016. T. 4. № 2. S. 42–44.
  17. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma // J. Clin. Oncol. 2006. № 24. R. 1443–1438.
  18. Vogelzang N.J. et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma // J. Clin. Oncol. 2003. V. 21. № 14. R. 2636−2644.